Eli Radiopharma funding, valuation and investors

Product & use cases

Research-stage diagnostic and therapeutic radiopharmaceuticals rather than a subscription software product. Diagnostic path (illustrative clinical-trial workflow, not a commercially available Eli service): a clinician screens an eligible patient under an approved protocol, nuclear-medicine staff obtain and administer the protocol's F-18 tracer, the patient receives a PET scan, trained readers interpret tracer uptake in conjunction with clinical data, and investigators assess safety/imaging endpoints. Therapeutic programmes pair tumour-targeting ligands with radionuclides, aiming to deliver radiation selectively; before any patient use as a marketed therapy, each candidate needs chemistry/manufacturing, toxicology, IND permission, human trials, safety and efficacy confirmation, and regulatory approval. The company has not disclosed validated product pricing, sales, named paying customers or commercial revenue. Distinguish investigational company claims from independent clinical proof. Sources: https://www.eliradiopharma.com/en/science/pipeline and https://www.eliradiopharma.com/en/newsroom/press-release/29 .

• Neurological imaging: protocol-approved evaluation of F-18 tau PET tracer ELI-101 in clinical research; not a general-purpose commercial booking service or proof of approved sales.
• Solid-tumour oncology: investigational matched diagnosis/treatment approach using targeted radioligands with Ga-68, Lu-177 or Ac-225 in experimental candidates.
• Biopharma business development: potential clinical research collaborations or licensing after milestone validation; current commercial partnership and licensing economics are not disclosed.

Key facts

• November 12, 2026: Series A announced at almost €54M using November 11 ECB FX as a converted upper reference; the issuer reports a 'nearly' amount, not an exact sum.
• Huagai Capital led the Series A; Bayland Capital was co-lead. Additional investors and participating existing holders are identified in the November 12 issuer release.
• ELI-101 is a neurological F-18 PET diagnostic candidate with clinical-trial authorization; this does not mean marketing approval or an established diagnostic service.
• ELI-301, ELI-411 and ELI-601 are experimental solid-tumour radiotheranostic programmes. Multiple targets are approaching IND filing, not necessarily in human trials.
• Earlier separate announcements: €13.2M approximate angel funding (December 2024); more than €12.0M converted Angel+ financing (September 2025); almost €12.6M converted new financing (March 2026). These figures use each original disclosure date's exchange rate and are not reclassified as Series A.

Competitive landscape

Edge: The company's claimed positioning is discovery of molecular targets, ligand optimization and integration of diagnostic/therapeutic isotopes. This is an R&D hypothesis, not independently established clinical superiority or commercial competitive moat. The company pipeline includes ELI-101 as co-development and in-house oncology projects; manufacturing isotope access, intellectual property and clinical readouts remain critical.

Investor diligence should separate diagnostic PET tracer ELI-101 trial progress from the cancer-radioligand preclinical assets, quantify medical-isotope supply and manufacturing readiness, inspect independently registered clinical safety/dosimetry data, and avoid extrapolating mature competitors' commercial results to Eli's unapproved pipeline. The 2026 Series A release cites promising in-vitro/in-vivo findings and candidates approaching IND; it does not present randomized efficacy outcomes, repeatable manufacturing yields, radiotracer revenue or disclosed post-money valuation. Lilly's FDA-approved Tauvid uses flortaucipir F-18, which further limits novelty claims around an F-18 tau tracer.

• Lilly Tauvid (flortaucipir F-18) direct

  An FDA-approved U.S. tau PET imaging diagnostic using flortaucipir F-18; not the same company as Eli Radiopharma. Eli's ELI-101 flortaucipir trial in China should not be represented as a new-to-world molecular target or a marketed product.

• Approved amyloid PET tracers adjacent

  PET diagnostics for amyloid pathology address different imaging targets from tau pathology; alternative clinical pathways rather than direct molecular equivalents.

• Novartis Pluvicto adjacent

  Approved targeted radionuclide therapy for a specified prostate-cancer indication; relevant proof that the modality can reach market, not evidence Eli's early oncology molecules work.

• Telix Pharmaceuticals adjacent

  Radiopharmaceutical diagnostics and therapies with different product portfolios and regulatory status; comparisons require indication- and stage-specific evaluation.

Market / IPO context